Prot #MK-3475-676: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cance

Project: Research project

Project Details

StatusActive
Effective start/end date4/18/224/18/25

Funding

  • Merck Sharp & Dohme Corporation (Prot #MK-3475-676)